1. Search Result
Search Result
Results for "

chronic obstructive pulmonary disease (COPD)

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

2

Inhibitory Antibodies

3

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156963

    FP-025

    MMP Inflammation/Immunology
    Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor. Aderamastat can be used for the research of asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis .
    Aderamastat
  • HY-D0205A

    Carbocysteine

    Carbocisteine, a mucolytic agent, can be used for the research of chronic obstructive pulmonary disease (COPD) .
    Carbocisteine
  • HY-15545

    CCR Neurological Disease Inflammation/Immunology Endocrinology
    AZD-4818 is a potent antagonist of chemokine CCR1. AZD-4818 can be used for researching chronic obstructive pulmonary disease (COPD) .
    AZD-4818
  • HY-19830

    Phosphodiesterase (PDE) Inflammation/Immunology
    AN3199 is a PDE4 inhibitor with an IC50 of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
    AN3199
  • HY-105092

    OPC-6535

    Phosphodiesterase (PDE) Inflammation/Immunology
    Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).
    Tetomilast
  • HY-153192

    BI 1015550

    Phosphodiesterase (PDE) Inflammation/Immunology
    Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .
    Nerandomilast
  • HY-153192A

    BI 1015550 dihydrate

    Phosphodiesterase (PDE) Inflammation/Immunology
    Nerandomilast (BI 1015550) dihydrate is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast (dihydrate) has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .
    Nerandomilast dihydrate
  • HY-108644

    p38 MAPK Inflammation/Immunology
    SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD) .
    SB 706504
  • HY-111144

    AZD0548; LAS100977

    Adrenergic Receptor Inflammation/Immunology
    Abediterol (LAS100977) is an inhaled long-acting β2-adrenoceptor agonist (LABA) and can be used for the research of asthma and chronic obstructive pulmonary disease (COPD) .
    Abediterol
  • HY-14144
    Aclidinium Bromide
    5 Publications Verification

    LAS 34273; LAS-W 330

    mAChR Inflammation/Immunology
    Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research .
    Aclidinium Bromide
  • HY-B0944

    Bacterial Inflammation/Immunology
    Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
    Pidotimod
  • HY-B1037S

    Albuterol-d3; AH-3365-d3

    Adrenergic Receptor Neurological Disease Endocrinology
    Salbutamol-d3 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
    Salbutamol-d3
  • HY-B1037S2

    Albuterol-d9; AH-3365-d9

    Isotope-Labeled Compounds Adrenergic Receptor Neurological Disease Endocrinology
    Salbutamol-d9 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
    Salbutamol-d9
  • HY-B1037S3

    Albuterol-d9 acetate; AH-3365-d9 acetate

    Adrenergic Receptor
    Salbutamol-d9 (acetate) is the deuterium labeled Salbutamol[1]. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
    Salbutamol-d9 acetate
  • HY-155692

    Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-13 is a PDE4 inhibitor with an IC50 of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties, and can be used for chronic obstructive pulmonary disease (COPD) research .
    PDE4-IN-13
  • HY-137976

    Penequinine hydrochloride

    mAChR NF-κB Inflammation/Immunology
    Penehyclidine (Penequinine) hydrochloride, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine hydrochloride activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine hydrochloride can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
    Penehyclidine hydrochloride
  • HY-142119

    mAChR NF-κB Inflammation/Immunology
    Penehyclidine, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
    Penehyclidine
  • HY-P99444
    Astegolimab
    1 Publications Verification

    MSTT 1041A; RG 6149

    Interleukin Related Inflammation/Immunology
    Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research .
    Astegolimab
  • HY-109177

    QBW251

    CFTR Inflammation/Immunology
    Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .
    Icenticaftor
  • HY-14189

    R-411

    Integrin Inflammation/Immunology
    Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
    Valategrast hydrochloride
  • HY-19672

    BAY 19-8004

    Phosphodiesterase (PDE) Inflammation/Immunology
    Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties .
    Lirimilast
  • HY-143721

    Monoamine Oxidase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
    SSAO inhibitor-2
  • HY-14190

    R-411 free base

    Integrin Inflammation/Immunology
    Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
    Valategrast
  • HY-143723

    Monoamine Oxidase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
    SSAO inhibitor-3
  • HY-119708

    RPL-554

    Phosphodiesterase (PDE) Inflammation/Immunology
    Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC50s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .
    Ensifentrine
  • HY-107046

    Adenosine Receptor Inflammation/Immunology
    UK-432097 is a highly potent and selective A2AAR agonist with a pKi of 8.4 for human A2AAR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research .
    UK-432097
  • HY-P99673

    REGN-3500; SAR-440340

    Interleukin Related NF-κB Inflammation/Immunology
    Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
    Itepekimab
  • HY-19644
    GSK2256294A
    2 Publications Verification

    GSK 2256294

    Epoxide Hydrolase Cardiovascular Disease
    GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease .
    GSK2256294A
  • HY-14301
    Olodaterol
    1 Publications Verification

    BI1744

    Adrenergic Receptor Inflammation/Immunology Endocrinology
    Olodaterol (BI1744) is a selective, long acting β2-adrenoceptor2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .
    Olodaterol
  • HY-14301A
    Olodaterol hydrochloride
    1 Publications Verification

    BI1744 hydrochloride

    Adrenergic Receptor Inflammation/Immunology Endocrinology
    Olodaterol (BI1744) hydrochloride is a selective, long acting β2-adrenoceptor2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis .
    Olodaterol hydrochloride
  • HY-B0241

    Sch 1000

    mAChR Neurological Disease Inflammation/Immunology
    Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .
    Ipratropium bromide
  • HY-B1332

    Sch 1000 bromide hydrate

    Ipratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .
    Ipratropium bromide hydrate
  • HY-B1037
    Salbutamol
    2 Publications Verification

    Albuterol; AH-3365

    Adrenergic Receptor ERK Inflammation/Immunology Cancer
    Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
    Salbutamol
  • HY-B0241S

    Sch 1000-d3

    mAChR Neurological Disease Inflammation/Immunology
    Ipratropium-d3 (bromide) is the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3].
    Ipratropium-d3 bromide
  • HY-124270

    AR-C68397AA

    Dopamine Receptor Adrenergic Receptor Inflammation/Immunology
    Sibenadet hydrochloride (AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist with bronchodilator activity. Investigation in animal models of key chronic obstructive pulmonary disease (COPD) symptoms has demonstrated that Sibenadet hydrochloride effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea.
    Sibenadet hydrochloride
  • HY-149235

    PI3K Inflammation/Immunology
    PI3Kδ-IN-12 (compound 13) is a PI3Kδ inhibitor (pIC50 = 5.8), with pKi values of 8.0/6.5/6.4/6.7 for PI3Kδ/γ/β/α, respectively. PI3Kδ-IN-12 can be used in the study of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
    PI3Kδ-IN-12
  • HY-14299
    Indacaterol
    4 Publications Verification

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
    Indacaterol
  • HY-136239
    Beclomethasone 17-propionate
    1 Publications Verification

    Beclomethasone-17-monopropionate; 17-BMP

    Glucocorticoid Receptor Drug Metabolite Inflammation/Immunology
    Beclomethasone 17-propionate (Beclomethasone-17-monopropionate), an active metabolite of Beclomethasone dipropionate (HY-13571), is a glucocorticoid receptor (GR) agonist. Beclomethasone 17-propionate exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppresses cytokine production in chronic obstructive pulmonary disease (COPD) lung macrophages .
    Beclomethasone 17-propionate
  • HY-B0241S1

    Sch 1000-d7 (bromide)

    mAChR Neurological Disease Inflammation/Immunology
    Ipratropium-d7 (bromide)eis the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3].
    Ipratropium-d7 bromide
  • HY-120595

    RV568

    p38 MAPK Src Inflammation/Immunology
    JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma .
    JNJ-49095397
  • HY-14299A
    Indacaterol maleate
    4 Publications Verification

    QAB149

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
    Indacaterol maleate
  • HY-146346

    PROTACs HDAC Inflammation/Immunology
    HD-TAC7 is a potent PROTAC HDAC degrader with IC50 values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decreases NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) .
    HD-TAC7
  • HY-151198

    mAChR Adrenergic Receptor Calcium Channel Inflammation/Immunology Endocrinology
    CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) .
    CHF-6366
  • HY-B1037R

    Albuterol (Standard); AH-3365 (Standard)

    Adrenergic Receptor ERK Inflammation/Immunology Cancer
    Salbutamol (Standard) is the analytical standard of Salbutamol. This product is intended for research and analytical applications. Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
    Salbutamol (Standard)
  • HY-18862

    PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .
    PF-03715455
  • HY-107909

    1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate

    Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Cancer
    Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .
    Theophylline sodium glycinate
  • HY-10790
    Cilomilast
    1 Publications Verification

    SB-207499

    Phosphodiesterase (PDE) Inflammation/Immunology
    Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 µM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .
    Cilomilast
  • HY-120802

    AZD-8871; LAS191351

    mAChR Adrenergic Receptor Inflammation/Immunology
    Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .
    Navafenterol
  • HY-150579

    Keap1-Nrf2 Inflammation/Immunology Cancer
    Keap1-Nrf2-IN-13 is a Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with an IC50 value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forming hydrogen bond with the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers .
    Keap1-Nrf2-IN-13
  • HY-120802A

    AZD-8871 saccharinate; LAS191351 saccharinate

    mAChR Adrenergic Receptor Infection Inflammation/Immunology
    Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol saccharinate can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .
    Navafenterol saccharinate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: